Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT05425992
- Status
- Recruiting
Conditions
- Leukemia
- Non Hodgkin Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 22 Years
- Healthy Volunteers
- Not accepted
Interventions
- Interview — OTHERPatient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
Study Details
This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.
Key Dates
- Start date
- Mar 17, 2022
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 20 participants (estimated)
Arms
- Arm: Patients treated in CCBDPatients who are currently receiving therapy at the Center for Cancer and Blood Disorders
Primary Outcome Measure
Determine a baseline level of Spanish speaking patient satisfaction of care [ Time Frame: 12 months ]
Central Contacts
- Wendy Moore1-720-777-6353
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's Hospital Colorado | Aurora | Colorado | 80045 | Ashley Rogers (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Aurora, CO
By condition
By specialty
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory LymphomaPHASE1 · Recruiting · Marker Therapeutics, Inc. · Duarte, California
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPHASE1 · Recruiting · Kura Oncology, Inc. · Gilbert, Arizona